MedTrace Logo

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

NCT02418481 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-07-19

No results posted yet for this study

Summary

In this study, effects of γδT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Conditions

Interventions

BIOLOGICAL

DC-CIK

DC-CIK cells will be used against tumor cells.

BIOLOGICAL

γδ T Cell

γδ T cells will be used against breast tumor.

BIOLOGICAL

Combination

γδ T/DC-CIK cells will be used against breast tumor.

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418481 on ClinicalTrials.gov